Dronabinol

TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce the Management Cease Trade Order (“MCTO”) issued on April 4, 2025 by the Ontario Securities Commission (“OSC”) has now been revoked. As previously announced, all required filings have been filed by the Company. Following the filing of required filings, the OSC has revoked the MCTO. Copies of the required filings are available on the Company’s SEDAR+ profile at www.sedarplus.ca. About Avicanna: Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders.Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. SOURCE Avicanna Inc. Stay Connected For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com. Cautionary Note Regarding Forward-Looking Information and Statements This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company’s annual information form dated April 11, 2025, filed with the Canadian securities regulators and available under the Company’s profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

TUESDAY, April 8, 2025 -- A non-intoxicating extract of cannabis appears to help children and teenagers with autism, a new study says. Cannabidiol (CBD) enhanced social responsiveness, reduced disruptive behavior and alleviated anxiety among kids with autism, researchers reported today at the European Congress of Psychiatry in Madrid. “The global population prevalence of autism spectrum disorder diagnosis amongst children and adolescents is growing, but many treatment pathways are not effective,” lead researcher Dr. Lara Branco , a psychiatrist at the University of São Paulo in Brazil, said in a news release. “It is promising to see the effect of CBD cannabis extract on the study participants,” she continued. For the study, researchers pooled data from three previous clinical trials looking into the use of CBD extracts to treat 276 children with autism. Their average age was 10-1/2 years old. Cannabidiol is the second most prevalent active ingredient in marijuana, according to Harvard Medical School. Unlike THC, CBD does not cause intoxication, but researchers believe it can produce health benefits by acting upon cannabinoid receptors throughout the brain and body. The new results show that CBD does indeed appear to have a calming effect on children with autism, helping them become more responsive to others and less anxious. CBD also appeared to improve kids’ sleep quality, although those results were not statistically significant. “ASD can be extremely frustrating for all involved; parents of children and adolescents with the disorder, the treating clinicians, and of course the children and adolescents themselves,” European Psychiatric Association President Dr. Geert Dom said in a news release. “A large part of this frustration is down to finding a viable treatment option that works to reduce symptoms,” added Dom, a professor of psychiatry at the University of Antwerp in Belgium. “It is with delight that we see the results of this meta-analysis and we hope to see further research into this so we can move towards a solution to the unmet need within this community." Branco, however, emphasized that more research into CBD is needed before it can be considered as a treatment for autism. “There still needs to be considerable focus on further research with larger trials to clarify its efficacy and safety in managing ASD,” she said. Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.